[ad_1]
Neuroleaf, a global leader in medical devices delivering breakthrough neurotechnology innovations for the treatment of neurological and neuropsychiatric disorders, is pleased to announce a strategic equity investment from Sawai Group Holdings, Inc. think. This investment strengthens Neuroleaf’s strategic collaboration with Japanese pharmaceutical companies.Companies that previously signed an exclusive agreement for the development and marketing of Neurolief’s His Relivion® – Pioneering non-invasive home wearable electrical therapy for migraines and depression Japan.
Recommended AI news: Riding the Generative AI Hype, CDP Will Need New Definition in 2024
Recommended AI news: Therap Services enhances business intelligence module to improve performance evaluation
scott driesNeuroleaf’s CEO said, “We are very pleased to receive this investment from Sawai Group Holdings, the parent company of our strategic partner Sawai Pharmaceutical Co., Ltd. “It not only emphasizes our vision,” he said.Disruptive technology to treat millions of patients suffering from migraines and depression JapanBut it also represents a common commitment to improving care for these debilitating chronic diseases. ”
Recommended AI news: Conduent Announces Agreement to Sell Curbside Management and Public Safety Business to Modaxo
Mitsuo Sawai, CEO of Sawai Group Holdings said, “Based on our corporate philosophy of “Always putting the patient first,” we are dedicated to contributing to healthier lives by introducing new and innovative treatments. ” With the introduction of Relivion® Expanding treatment options for patients suffering from migraines and depression by enabling home treatment under the supervision of a physician. ”
[To share your insights with us, please write to sghosh@martechseries.com]
[ad_2]
Source link
